Novel Biologics & Biosimilars

Paras Biopharmaceuticals' Novel Biologics and Biosimilar Pipeline & Technologies

Novel Biologics and Biosimilars Pipeline

Paras Biopharma Novel Biologics

Paras Biopharma Novel Biologics approach and portfolio pipeline comprises of Biologics for Rare & Orphan Diseases and Novel applications in Multiple Myeloma, Respiratory, Gout, Pulmonary Arterial Hypertension, Osteoarthritis, and Knee Fibrosis.

Multiple Myeloma Respiratory Gout Pulmonary Arterial Hypertension Osteoarthritis Knee Fibrosis

Paras Biopharma Biosimilars

Paras Biopharma Biosimilar approach and portfolio pipeline comprises of unique biosimilars that have niche indications, low competition, high value and growing market opportunity, and low risk for development. Product pipeline includes biosimilar candidates of Oncology, Osteoporosis, Rheumatoid Arthritis, and Metabolic Diseases.

Oncology Osteoporosis Rheumatoid Arthritis Metabolic Diseases
Biosimilar Overview

Paras Biopharmaceuticals is committed to innovation of high-quality products and technologies. The Company has developed robust biosimilars development technologies for the following medical areas:

Oncology products for: multiple myeloma, platelet disorder, and tumor lysis syndrome.

Biosimilar Technologies/Product Pipeline
Paras Biopharma Product / Biosimilars Target Disease Brand Name(INN Name) Description Technology Platform
PB (Osteo)-1010 Osteoporosis Diabrid Technology / NobleCleav Technology Biosimilar candidate to Forteo® DiabridTechnology / NobleCleavTechnology
PB (RA)-2010 Rheumatoid Arthritis IL-KTM(Anakinra) Biosimilar candidate to Kineret® High Expression Technology
PB (MDT)-3010 Type I and II Diabetes Asplin(Insulin Aspart) Biosimilar candidate to Novolog® Diabrid Technology / NobleCleavTechnology
PB (CT)-4020 Oncology (Platelet Disorders) Romi-Multiplat (Romiplostim) Biosimilar candidate to Nplate® Biomultifold Technology
PB (CT)-4030 Oncology (Tumor Lysis Syndrome) Raspa (Rasburicase) Biosimilar candidate to Elitek® High Expression Technology

Disclaimer

Products under patents are part of our research projects. These products may be offered only in those countries where patents have expired.

For the latest status, please contact Paras Biopharmaceuticals Finland Oy.

Forteo, Kineret, Elitek, Nplate,and Novolog are registered trademarks of/marketed by Eli Lilly, Sobi/Amgen, Amgen, Sanofi and Novo Nordisk respectively. *Source GlobalData

Paras Biopharma Product / Biosimilars Target Disease Brand Name(INN Name) Description Development Stage
PB (RA)-2020 Rheumatoid Arthritis Ceras-peg(certolizumab) Biosimilar candidate to Cimzia® Under development
PB (CT)-4040 Multiple Novel Applications IL-MTM Biobetter candidate to IL-1 RA Under development
PB (CT)-4010 Oncology (Multiple Myeloma) IL-BTM Biobetter candidate to IL-1 RA Under development
PB (OA)-5010 Osteoarthritis IL-OTM Osteoarthritis patch of IL-1 RA Under development

Disclaimer

Products under patents are part of our research projects. These products may be offered for further development only in thosecountries where patents have expired. For the latest status, pleasecontactParas Biopharmaceuticals Finland Oy.

Cimzia is a registered trademarks of/marketed by UCB. *Source GlobalData

Unique Features

Paras Biopharmaceuticals innovative technology platform, along-with other associated process technologies, enables a very high and economical way to develop biosimilars for scale-up production.

The Paras Biopharmaceuticals’ Team has successfully developed a multiple biosimilar in its pipeline for “Rare & Orphan diseases” which are now available in the company’s portfolio for partnership.

Biosimilars Pipeline & Technologies

Development of Recombinant Expression Systems & Process Technologies for Biologics & Biosimilars:

Paras Biopharmaceuticals is actively engaged in research & development and is offering partnership for further development (including clinical development) on the following biosimilars:

Due to its own technologies, Paras Biopharmaceuticals has achieved efficient and cost-effective ways which would help in the efficient production of some high value biosimilars. This development is based on Paras Biopharmaceuticals’ proprietary technology platform which includes Diabrid , Noblecleav , Biomultifold & CytofoldStructQuant technologies.

Forteo, Kineret and Nplate are registered trademarks of/marketed by Eli Lilly, SobiSweden and Amgen USA respectively * Source GlobalData

Biosimilars Technologies/Product Pipeline
Paras Biopharmaceuticals Biosimilar pipeline Terishield IL-KTM Asplin
Reference Product Forteo® Kineret® Novolog®
Major Approved indications Postmenopausal Osteoporosis Rheumatoid Arthritis, CAPS#, DIRA* Diabetes Mellitus
2020 Global sales* $ 1076m $ 220m $ 4385m
Development stage Scale-up production and comparison Scale-up production and comparison Pre-clinical (high expression achieved)

Disclaimer

Products under patents are part of our research projects. These products may be offered for further development only in thosecountries where patents have expired. For the latest status, pleasecontactParas Biopharmaceuticals Finland Oy.

Forteo, Kineret, and Novolog are registered trademarks of/marketed by Eli Lilly, Sobi/Amgen, and Novo Nordisk respectively * Source Globaldata

Paras Biopharmaceuticals Biosimilar pipeline Romi-MultiPlat Raspa Ceras-Peg
Reference Product Nplate® Elitek® Cimzia®
INN Romiplostim Rasburicase Certolizumab-pegol
Major Approved indications Immune Thrombocytopenia Mgmt. of plasma uric acid levels in oncology patients TNF blocker indicated for Rheumatoid Arthritis and others
2020 Global sales* $ 920m $ 170m $ 210m
2025 Sales estimates* $ 964m $ 314m $ 1847m
Development stage Scale-up production & biosimilarity/ Pre-clinical Under development (high expression achieved) Under development

Disclaimer

Products under patents are part of our research projects. These products may be offered for further development only in thosecountries where patents have expired. For the latest status, pleasecontactParas Biopharmaceuticals Finland Oy.

Nplate, Elitek, and Cimzia are registered trademarks of/marketed by Amgen, Sanofi, and UCB respectively * Source Globaldata

PB (Osteo)-1010 (Biosimilar candidate to Forteo®)

Osteoporosis

Brand Name:
Terishield
INN:
Teriparatide
Reference Product:
Forteo®

Forteois a registered trademark of/marketed by Eli Lilly.

PB (Osteo)-1010 (Osteoporosis)

Product Status:

Technology Status

PB (RA)-2010 (Biosimilar candidate to Kineret®)

Rheumatoid Arthritis

Brand Name:
IL-KTM
INN:
Anakinra
Reference Product:
Kineret®

Kineret is a registered trademark of/marketed by Sobi/Amgen.

PB (RA)-2010 (Rheumatoid Arthritis)

Product Status:

Technology Status

PB (MDT)-3010 (Biosimilar candidate to Novolog®)

Diabetes (Metabolic Disorders)

Brand Name:
IL-KTM
INN:
Anakinra
Reference Product:
Kineret®

Novolog is a registered trademark of/marketed by Novo Nordisk.

PB (MDT)-3010 (Diabetes)

Product Status:

Technology Status

Advantages of Biosimilars
Salient Features Small Molecule Biosimilars (follow-on biologics) Novel Biologics
Market entry barriers Low High -(Technology and scientific knowhow available with Paras Biopharmaceuticals) High
Product development costs Low Medium Very High
Price advantage Low -(high discount on innovator molecule price) High -(low discount on reference product price) N.A.
USPs First to market and low price Low competition -(Niche product dev. capabilities by Paras Biopharmaceuticals) Differentiated therapies;
Paras Biopharmaceuticals Business Model

Paras Biopharmaceuticals has generated an authentic and well-characterized biosimilars production process using its Diabrid , NobleCleav & Biomultifold technologies

Company’s business model works on the following features:

1. In-house biosimilar development has established an economical production process & extensive characterization.

2. Collaboration with (bio)pharmaceutical companies for clinical development / commercialization.

Biosimilar Market Insights
Osteoporosis Market Insights
Diabetes & Insulin Market Insights